Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. (“Conduit”) on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments. Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit’s issued share capital. At the closing mid-market price of $0.17 on 8 August 2024,…

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee company Conduit Pharmaceuticals has entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms of the License Agreement,…

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Address

Contact

Social

LEGAL